Evidence map›Paper›PMID 23419026›Full record

ArticleJournal of medicinal chemistry2013

Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands.

Henry I Mosberg, Larisa Yeomans, Aubrie A Harland, Aaron M Bender, Katarzyna Sobczyk-Kojiro, Jessica P Anand, Mary J Clark, Emily M Jutkiewicz, John R Traynor

Open access · greenAbstract read
In one paragraph

Article in Journal of medicinal chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Tryptophan Substitution in CJ-15,208 (Pharmaceuticals (Basel, Switzerland) · 2023
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Novel Pharmacological Nonopioid Therapies in Chronic Pain.Current pain and headache reports · 2018
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Henry I MosbergDepartment of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States. him@umich.edu
Larisa Yeomans
Aubrie A Harland
Aaron M Bender
Katarzyna Sobczyk-Kojiro
Jessica P Anand
Mary J Clark
Emily M Jutkiewicz
John R Traynor
University of Michigan–Ann Arbor · US

Funding

INTERDEPARTMENTAL TRAINING IN PHARMACOLOGICAL SCIENCEST32GM007767 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ISOM, LORI L. · 1985 to 2019
$10.2M
Development of Mixed Function Opioid Peptides and PeptidomimeticsR01DA003910 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MOSBERG, HENRY ISAAC · 1985 to 2017
$9.0M
NIDA Training Program in Neuroscience-Administrative SupplementT32DA007281 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Shelly Beth Flagel · 1995 to 2026
$5.7M
SUBSTANCE ABUSE INTERDISCIPLINARY TRAINING PROGRAMT32DA007267 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GNEGY, MARGARET E · 1994 to 2015
$4.5M
OPIOID RECEPTOR MECHANISMSR01DA004087 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI TRAYNOR, JOHN R. · 1987 to 2010
$2.5M
NIDA NIH HHS DA003910NIDA NIH HHS DA004087NIDA NIH HHS DA007267NIDA NIH HHS DA007281NIDA NIH HHS R01 DA003910NIDA NIH HHS R01 DA004087NIDA NIH HHS T32 DA007267NIDA NIH HHS T32 DA007281NIGMS NIH HHS GM007767NIGMS NIH HHS T32 GM007767
6 · The paper itself

Abstract

We have previously described opioid peptidomimetic, 1, employing a tetrahydroquinoline scaffold and modeled on a series of cyclic tetrapeptide opioid agonists. We have recently described modifications to these peptides that confer a μ opioid receptor (MOR) agonist, δ opioid receptor (DOR) antagonist profile, which has been shown to reduce the development of tolerance to the analgesic actions of MOR agonists. Several such bifunctional ligands have been reported, but none has been demonstrated to cross the blood-brain barrier. Here we describe the transfer of structural features that evoked MOR agonist/DOR antagonist behavior in the cyclic peptides to the tetrahydroquinoline scaffold and show that the resulting peptidomimetics maintain the desired pharmacological profile. Further, the 4R diastereomer of 1 was fully efficacious and approximately equipotent to morphine in the mouse warm water tail withdrawal assay following intraperitoneal administration and thus a promising lead for the development of opioid analgesics with reduced tolerance.

Indexed as

AnalgesicsAnalgesics, OpioidAnimalsCHO CellsCricetinaeDrug ToleranceLigandsMicePeptidomimeticsPhenylpropionatesQuinolinesRatsReceptors, Opioid, deltaReceptors, Opioid, mu2-amino-N-(6-benzyl-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-dimethylphenyl)propanamideAnalgesicsAnalgesics, OpioidLigandsPeptidomimeticsPhenylpropionatesQuinolinesReceptors, Opioid, deltaReceptors, Opioid, mu

Identifiers

PMID23419026
PMCPMC3618660
OpenAlexW2013107372

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.